Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response

12 of 12 participants (100%) in the 180mg cohort achieved a clinical response

Read more at globenewswire.com